Cells and animals deficient in protein kinase c epsilon

Details Cells and animals deficient in protein kinase c epsilon Cells and animals deficient in protein kinase c epsilon

A - Human Necessities

61

K

A61K 38/45 (2006.01) A01K 67/027 (2006.01) A61K 31/197 (2006.01) A61K 31/515 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) A61K 45/06 (2006.01) A61P 25/22 (2006.01) A61P 25/30 (2006.01) C12N 5/10 (2006.01) C12N 9/12 (2006.01) C12N 15/85 (2006.01) C12Q 1/00 (2006.01) C12Q 1/48 (2006.01)

Patent

CA 2332488

The present invention is directed to the production of PKC isozyme epsilon (PKCepsilon)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsilon as a target for drugs that reduce anxiety. According to the present invention, PKCepsilon-inhibiting compounds act in synergy with drugs acting at the GABAalpha receptor. The present invention is also directed to the use of modulators of PKCepsilon to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumptions as well as the use of inhibitors of PKCepsilon, either alone or in conjunction with allosteric agonists of GABAalpha receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAalpha receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods.

L'invention concerne la production de cellules et animaux non-humains déficients en PKC isozyme epsilon (PKCepsilon). L'invention concerne également l'identification de PKCepsilon en tant que cible pour médicaments réduisant l'anxiété. Conformément à l'invention, des composés inhibiteurs de PKCepsilon agissent en synergie avec des médicaments agissant sur le récepteur GABAalpha. L'invention concerne en outre l'utilisation de modulateurs de PKCepsilon pour moduler la consommation d'alcool, l'auto-administration de drogues à usage immodéré, et les effets de la consommation d'alcool, ainsi que l'utilisation d'inhibiteurs de PKCepsilon, soit seul, soit conjointement avec des agonistes allostériques de récepteurs GABAalpha pour le traitement d'états tels que toxicomanie, syndrome de privation, spasmes des muscles squelettiques, crises convulsives et épilepsie qui relèvent du traitement par des agonistes allostériques de récepteurs GABAalpha. L'invention concerne également, suivant d'autres aspects, des méthodes de diagnostic pour l'identification d'individus à risque alcoolique ou à consommation abusive de drogues, ainsi que des kits pour la mise en oeuvre de telles méthodes de diagnostic.

Affiliated with

Also associated with

Rating

Cells and animals deficient in protein kinase c epsilon does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cells and animals deficient in protein kinase c epsilon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cells and animals deficient in protein kinase c epsilon will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1557833